Board of Directors

Applying best practices from biotech and pharma to support Aimmune’s growth

Greg Behar is Chief Executive Officer of Nestlé Health Science, a wholly owned subsidiary of Nestlé that is engaged in advancing the role of nutritional therapy to change the course of health for consumers, patients and its partners in healthcare. Previously, Mr. Behar was President and Chief Executive Officer of Boehringer Ingelheim Pharmaceuticals Inc. (USA) and Corporate Vice President Region NECAR (North European Union, Canada and Australasia) for Boehringer-Ingelheim GmbH. He also spent seven years in marketing and sales leadership in various roles at Novartis, following earlier work at Nestlé.
Mr. Behar also serves on the boards of Accera, Inc., Axcella Health, Inc., and Seres Therapeutics, Inc. (Nasdaq:MCRB). Mr. Behar is Chairman of the Board of Nutrition Science Partners and a member of the Steering Committee of Nestlé Institute of Health Sciences. Mr Behar received his bachelor’s degree from the University of California, Los Angeles, his master’s degree in Mechanical Engineering and Manufacturing from EPFL in Switzerland, and an MBA from INSEAD in France.
Jayson Dallas, MD, is Aimmune’s President and Chief Executive Officer. In more than two decades in the pharmaceutical and biotech industry, Dr. Dallas has successfully overseen multiple product launches, internationally and in the United States, and has led numerous commercial organizations through periods of rapid growth. Prior to joining Aimmune, Dr. Dallas was Ultragenyx Pharmaceutical’s first Chief Commercial Officer, where he oversaw commercial operations, including sales, marketing, reimbursement and new product planning, and led the launches of the company’s first two products. Dr. Dallas also spent five years at Roche as General Manager of Roche in the United Kingdom and as head of global commercial strategy groups at Genentech, focused on oncology, immunology and ophthalmology. Earlier, Dr. Dallas headed the specialty medicines operating unit for Novartis in the United States, after holding several leadership roles of increasing responsibility within the company.
He also held significant medical and marketing positions as he built his career at Pfizer, Roche and Proctor & Gamble Pharmaceuticals. In his career, Dr. Dallas has played important roles in the launch and lifecycle management of numerous drugs, including Crysvita®, Mepsevii®, Herceptin®, Rituxin®, Actemra®, Lucentis®, Exelon® Patch, Trileptal®, Somavert®, Genotropin®, Xenical® and Didronel®. Before joining the pharmaceutical industry, Dr. Dallas practiced medicine in South Africa and in the United Kingdom, and worked as a research physician. Dr. Dallas holds an MD from the University of the Witwatersrand in Johannesburg, South Africa, and an MBA from Ashridge in Berkhamsted, United Kingdom. He is currently a member of the board of directors of Arena Pharmaceuticals, Inc.
Patrick Enright is a founder and Managing Director of Longitude Capital. Previously, Mr. Enright was a Managing Director of Pequot Ventures. Prior to Pequot, he was a Managing Member responsible for the Delta Opportunity Fund. Mr. Enright began his investment career at PaineWebber Development Corporation, a direct investment group focused primarily on biotechnology companies. He also has significant life sciences operations experience, including senior executive positions at Valentis, Boehringer Mannheim Pharmaceuticals (now Hoffmann-La Roche) and Sandoz (now Novartis).
Mr. Enright currently serves on the boards of Esperion Therapeutics (Nasdaq:ESPR), Jazz Pharmaceuticals (Nasdaq:JAZZ) and several privately held companies. He previously served on the boards of Corcept Therapeutics (Nasdaq:CORT), Codexis (Nasdaq:CDXS), Horizon Therapeutics (acquired), MAP Pharmaceuticals (Nasdaq:MAPP), Prestwick Pharmaceuticals (acquired), Threshold Pharmaceuticals (Nasdaq:THLD) and Sequenom (Nasdaq:SQNM). Mr. Enright holds an MBA from the Wharton School of Business at the University of Pennsylvania and a BS in Biological Sciences from Stanford University.
Kathryn “Kate” Falberg is Chair of the Audit Committee for the Aimmune Board of Directors and serves as a Board Member and Audit Committee Chair for several life sciences companies. Ms. Falberg currently serves as a Director and Chair of the Audit Committee of Halozyme Therapeutics (Nasdaq:HALO), where she is also Chairperson of the Board, and at privately held aTyr Pharma. She previously served on the boards of Medivation, Ariosa Diagnostics, QLT, VISX, Fresh Del Monte and Human Genome Sciences.
In over four years as Chief Financial Officer of Jazz Pharmaceuticals, Ms. Falberg led finance, strategy and corporate development and contributed to the company’s rapid growth. Earlier in her career she held several senior financial roles at Amgen, including SVP, Strategy, and CFO. Ms. Falberg received an MBA and BA in Economics from the University of California, Los Angeles, and is a CPA.
Mark Iwicki is Executive Chairman of the Board of Directors of Kala Pharmaceuticals and sits on the Boards of Nimbus Therapeutics and Taris Biomedical. He was President and CEO of Civitas Therapeutics until late 2014, when it was acquired by Acorda Therapeutics. Prior to joining Civitas, Mr. Iwicki was President and CEO of Blend Therapeutics, a nanotechnology oncology biotech company. He was also President and CEO of Sunovion Pharmaceuticals after leading its launch from the acquisition of Sepracor, where he had been Chief Commercial Officer.
Previously, Mr. Iwicki was Senior Vice President at Novartis Pharmaceuticals and headed the cardiovascular business unit and additional therapeutic areas. He began his career in sales and marketing at Merck, Astra Merck and AstraZeneca. Mr. Iwicki received an MBA from Loyola University Maryland and a BS in Business Administration and Management from Ball State University.
Mark McDade is Chairman of the Aimmune Board of Directors and a founding partner with Qiming’s new U.S. Healthcare Fund, just raised in January 2017. Prior to joining Qiming, he served as Executive Vice President and Chief Operating Officer of UCB, a Belgian biopharma, from early 2008 until retiring from UCB in the fourth quarter of 2016. Prior to UCB, Mr. McDade served as Chief Executive Officer and on the board of directors of PDL BioPharma; Chief Executive Officer of Signature BioScience; co-founder, President and Chief Operating Officer at Corixa Corporation; and Chief Operating Officer of Boehringer Mannheim Therapeutics, the biopharmaceutical division of Corange Limited. He also held numerous business development and general management positions at Sandoz Ltd.
Mr. McDade serves on the Boards of Directors of Five Prime Therapeutics (Nasdaq:FPRX) and Dermira (Nasdaq:DERM). He received an MBA from the Harvard Business School and a BA in History from Dartmouth College.
Stacey Seltzer is a partner at Aisling Capital. Previously, Ms. Seltzer was at Schering-Plough, where she held roles in business development, marketing and sales, most recently serving as the U.S. Schering-Plough Brand Lead for Zetia. Prior to Schering-Plough, Ms. Seltzer was the Director of Business Development for Akceli, a biotechnology company developing cell-based microarrays. Ms. Seltzer began her career as a management consultant for McKinsey & Company. Ms. Seltzer serves as a director of Miramar Labs. Previously, she served as a Board observer for Agile Therapeutics, Durata Therapeutics and ZELTIQ Aesthetics.
Ms. Seltzer also acted as the Aisling representative for its investment in Precision Dermatology and was closely involved in Aisling’s investments in Cytos, Dermira and PowerVision. Ms. Seltzer received her MBA from The Wharton School at the University of Pennsylvania, where she was a Palmer Scholar. She received her MS and BS from Yale University, awarded cum laude in Molecular Biophysics and Biochemistry.